Pharminox makes board appointment
This article was originally published in Scrip
Executive Summary
Pharminox has appointed Dr Marc Hummersone to its board of directors as research director. Dr Hummersone joined the company from KuDOS Pharmaceuticals in April 2008 as head of chemistry. The UK-based cancer drug discovery and development company has also announced that Professor Malcolm Stevens is standing down from the board and as chief scientific officer, and will take up the honorary position of CSO Emeritus.
You may also be interested in...
Adeona makes appointment
Adeona has appointed Julie Caudill vice-president of finance and corporate controller. Ms Caudill has more than 15 years' biotechnology-related accounting and Securities and Exchange Commission compliance experience, having previously served as corporate controller and corporate secretary at Aastrom and as accounting manager at KMS Industries.
New CEO at CMP Therapeutics
CMP Therapeutics (UK) has appointed Dr Neill Moray Mackenzie chief executive officer. He succeeds Dr Bruce Savage, who is leaving the company. Dr Mackenzie has management experience in the pharmaceutical and biotech industries, having most recently served as senior vice-president for business development and corporate strategy at Medigene and as CEO of Roji.
New appointment at Calistoga
Calistoga Pharmaceuticals (US) has named Langdon Miller executive vice-president of R&D. Dr Miller has more than 20 years' drug development experience, with previous roles including chief medical officer at PCT Therapeutics and vice-president of global oncology clinical research at Pharmacia.